Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845243 | 0.86 | EGFR (0.77) | EGFRERBB2AURKAINSRFBP1 | |
| SCHEMBL5843864 | 0.86 | EGFR (0.78) | EGFRPDGFRB | |
| SCHEMBL5844206 | 0.86 | EGFR (1.00) | EGFRERBB2AURKAINSRFBP1 | |
| SCHEMBL15928222 | 0.80 | EGFR (0.89) | EGFRERBB2AURKAINSRFBP1 | |
| SCHEMBL5842950 | 0.80 | EGFR (0.82) | EGFRERBB2PDGFRB | |
| SCHEMBL15928071 | 0.78 | EGFR (1.00) | EGFRERBB2AURKAINSRFBP1 | |
| SCHEMBL15928221 | 0.77 | EGFR (0.75) | EGFRERBB2 | |
| SCHEMBL28403915 | 0.76 | EGFR (0.74) | EGFRERBB2AURKAINSRFBP1 | |
| SCHEMBL16449752 | 0.73 | EGFR (1.00) | EGFRPDGFRB | |
| SCHEMBL6794421 | 0.73 | EGFR (0.63) | EGFRERBB2AURKAINSRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078409-B2 | Fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. (US) | 2006-07-18 | — | — | US | claimed |
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. | 2004-03-11 | — | — | US | claimed |
| US-7078409-B2 | Fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | ABL1, ERBB2, CNKSR1 | EGFR 82/4885ERBB2 2/4885AURKA 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.